Coya Therapeutics, Inc. (COYA)

Every figure this model derived for COYA, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
cash 43,181,002 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 47,057,737 AssetsCurrent 2026-06-30
current liabilities 3,512,431 LiabilitiesCurrent 2026-06-30
equity 43,276,011 StockholdersEquity 2026-06-30
ocf -15,722,176 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 8,019,145 Revenues 2026-06-30
sbc 5,313,947 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up COYA on one particular measure came for.

RatioValue
cash operating margin-222.19
current ratio20.65
current ratio reported13.4
deferred revenue growth68.72
dilution pct9.79
fcf margin-196.06
operating margin-288.7
owner earnings margin-262.32
revenue growth1793.76
revenue growth per share1624.83
roic-19250.05
rule of 401505.06
sbc pct revenue66.27

What to be careful about

What this model itself distrusts about COYA's figures. Written by the derivation as it ran, not added afterwards.